Patented biomarker for cardiac injury. 

Patented biomarker for cardiac injury. 

Insights into the Novel Cardiac Biomarker in Acute Heart Failure: MyBP-C

The study brings new evidence supporting the role of MyBP-C as a comprehensive biomarker in AHF. While NT-proBNP remains the gold standard biomarker in AHF, MyBPC has been shown to have an impressive diagnostic performance with high sensitivity and specificity, providing complementary information. MyBP-C may serve as a valuable adjunctive tool in enhancing diagnostic accuracy and guiding clinical decisions in AHF.
In addition, MyBP-C has a promising role as a prognostic biomarker in AHF, being able to complement existing markers, and thus achieve better risk stratification and the prediction of short-term outcomes.

cMyC (Cardiac Myosin-binding protein C)
cMyC (Cardiac Myosin-binding protein C)